Arūnas Valiulis
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Respiratory and Cough-Related Research
- Delphi Technique in Research
- Health and Medical Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Child and Adolescent Health
- Neonatal Respiratory Health Research
- Food Allergy and Anaphylaxis Research
- Dermatology and Skin Diseases
- Olfactory and Sensory Function Studies
- Ethics and Legal Issues in Pediatric Healthcare
- Behavioral Health and Interventions
- Cystic Fibrosis Research Advances
- Pharmaceutical studies and practices
- COVID-19 Clinical Research Studies
- Pediatric health and respiratory diseases
- Protease and Inhibitor Mechanisms
- Air Quality and Health Impacts
- Health Systems, Economic Evaluations, Quality of Life
- Peptidase Inhibition and Analysis
- Adolescent and Pediatric Healthcare
- Childhood Cancer Survivors' Quality of Life
- Respiratory Support and Mechanisms
Vilnius University
2016-2025
European Union of Medical Specialists
2014-2024
The European Academy of Gynaecological Surgery
2015-2023
European Academy of Technology and Innovation Assessment
2014-2022
Lietuvos Bioetikos Komitetas
2020-2022
Vilnius University Hospital Santariskiu Klinikos
2020-2022
Charité - Universitätsmedizin Berlin
2019-2021
Sanofi (France)
2021
Takeda (Italy)
2021
Novartis (Ireland)
2021
The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious transmitted by the severe acute respiratory syndrome (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in field of allergies associated airway diseases are on front line, taking care patients potentially infected with SARS-CoV-2. Hence, strategies practices to minimize risks infection for both HCPs treated have be developed followed allergy clinics.The scientific information COVID-19 was analysed...
Although there are many asymptomatic patients, one of the problems COVID-19 is early recognition disease. symptoms polymorphic and may include upper respiratory symptoms. However, be mistaken with common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate between three diseases.A modified Delphi process was used. The ARIA members who were seeing patients asked fill in a questionnaire on airway COVID-19, rhinitis.Among 192 invited respond questionnaire, 89...
Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed use real-life data from MASK-air® app generate and validate hypothesis- data-driven CSMSs.We used assess concurrent validity, test-retest reliability responsiveness one hypothesis-driven CSMS (modified CSMS: mCSMS), mixed score (mixed score), several CSMSs. The latter were generated with following cluster analysis regression models or factor analysis....
Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This particularly relevant since AR understood differently across European countries, as reflected by rhinitis-related search in Google Trends. study aims to assess co-medication regional Europe, using real-world data. We analysed 2015-2020 MASK-air® compared days under no medication, monotherapy the visual analogue scale (VAS) levels for overall symptoms ('VAS Global Symptoms')...
MASK-air
Validated questionnaires are used to assess asthma control over the past 1-4 weeks from reporting. However, they do not adequately capture in patients with fluctuating symptoms. Using Mobile Airways Sentinel Network for airway diseases (MASK-air) app, we developed and validated an electronic daily score (e-DASTHMA).We MASK-air data (freely available users 27 countries) develop different scores asthma. Data-driven were based on symptoms reported by a visual analogue scale (VAS) self-reported...